search
Back to results

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Primary Purpose

Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Status
Not yet recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Sponsored by
Fondazione Italiana Linfomi - ETS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Classical Hodgkin Lymphoma focused on measuring Survivorship Care Plan, Lifestyles implemented-Survivorship Care Plan, Quality of Life, Lymphoma Survivors, Nutritional plan, Physical activity

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18-50 at initial treatment; Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL) or Primary mediastinal large B-cell lymphoma (PMBCL); Patients in Complete Remission (CR) after first-line therapy [ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin , cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2 guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adapted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL); Patients in remission for a minimum 3 years since the last treatment and a maximum of 10 years; Cumulative doxorubicin/ adriamycin dose received of at least 200 mg/mq (4 cycles of chemotherapy); Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensional speckle strain echocardiography) performed no later than three months prior to enrollment; Signature of a written informed consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate voluntarily in the study. Exclusion Criteria: Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers and adequately treated cone-biopsied in situ carcinoma of the cervix; Second line chemotherapy of stem cell transplant; Not able to perform physical activity; Grade >/=3 neuropathy; Vertebral fractures or stenosis of the vertebral canal; other bone fracture; Cardiovascular disease: arrhythmia >/= grade 2, hypertension >/ grade 2, left ventricular dysfunction >/= grade 2 pericardial disease/effusion any grade, myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathy any grade valvular hearth disease >/= grade 2, right ventricular dysfunction >/= grade 2; Venous thromboembolism or arterial thrombosis during last 6 months; Hemorrhage/ bleeding >/= grade 2 during last 6 months; Chronic lymphedema (arms and/ or limbs); Rheumatic disease or inflammatory bowel disease in systemic treatment; Any pleural effusion; If female, the patient is pregnant; Unwilling to comply to all required visits and procedures for the duration of study participation

Sites / Locations

  • Ancona - AOU Ospedali Riuniti - Clinica di Ematologia
  • Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati
  • Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia Cellulare
  • Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia
  • Ospedale S. Martino - UOC Oncologia
  • Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.
  • ASST Spedali Civili di Brescia - Ematologia
  • Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di Midollo
  • PO Sant'Elia ASP Caltanisetta - UOC Ematologia
  • Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia
  • Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Emtologia
  • Ospedale Generale di zona Valduce - Oncoematologia
  • Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di Ematologia
  • Ospedale Vito Fazzi - Ematologia
  • ASST Ovest Milanese - Legnano - U.O.C. Ematologia Ospedale Civile di Legnano
  • AOU G. Martino - U.O.C. Ematologia
  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
  • IEO Istitito Europeo di Oncologia - Divisione Ematoncologia
  • Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda - Ematologia
  • Azienda Ospedaliero-Universitaria Policlinico di Modena - U.O. Oncologia
  • AOU Maggiore della Caritа di Novara - SCDU Ematologia
  • AOU di Padova - Ematologia
  • I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1
  • Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia
  • AOU Policlinico Giaccone - Ematologia
  • P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi
  • Ospedale Guglielmo da Saliceto - U.O.Ematologia
  • AOU Pisana - U.O. Ematologia
  • A.O.R. "San Carlo" - U.O. Ematologia
  • Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia
  • Ospedale degli Infermi di Rimini - U.O. di Ematologia
  • AO Sant'Andrea - Ematologia
  • Ospedale S. Eugenio - UOC Ematologia
  • Policlinico Tor Vergata - Ematologia
  • Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare
  • Istituto Clinico Humanitas - U.O. Ematologia
  • AOU di Sassari - Ematologia
  • Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico
  • A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria
  • Ospedale Ca Foncello - S.C di Ematologia

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Arm (C)

Experimental Arm (E)

Arm Description

Patients in the control arm will not receive any Survivorship Care Plan (SCP) or intervention and will be followed-up according to the best clinical practice, with questionnaires self-administration at 6 and 12 months from randomization.

Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity indication) for 6 months.

Outcomes

Primary Outcome Measures

Global quality of life
The endpoint will be assessed by the European Organisation For Research And Treatment Of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) that will be submitted to patients. The EORTC QLQ-C30 consists of 30 items including five functioning scales (physical functioning, social functioning, role functioning, emotional functioning and cognitive functioning), nine symptom scales (fatigue, pain, nausea-vomiting, dyspnoea, sleep disturbances, appetite loss, diarrhoea, constipation and financial difficulties), and a global health status or quality of life (QOL) scale. On the 100-point metric, high scores for functioning scales and the global health status, or QOL, scale indicate high HR (health-related) QOL, while high scores on the symptom scales indicate a high symptom burden.

Secondary Outcome Measures

Impact of health on an individual's everyday life
The endpoint will be assessed by the 12-Item Short Form Survey (SF-12) which will be submitted to patients. Survey scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Changes in psychosocial well-being
The endpoint will be assessed by Hospital Anxiety and Depression Scale (HAD-S) questionnaire which will be submitted to patients. The HAD-S questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Overall survival (OS)
Overall survival, the percentage of patients alive of the cohort
Frequencies of chronic fatigue (FAS);
The number of times chronic fatigue is recorded in the cohort of patients
Cognitive function
The endpoint will be assessed by Cognitive Functioning Self-Assessment Scale (CFSS) questionnaire which will be submitted to patients. The Cognitive Functioning Self-Assessment Scale (CFSS) is a questionnaire designed for the self-reporting of cognitive functioning. Its 18 items cover cognitive domains such as attention, memory and spatial-temporal orientation. Each item describes an activity of daily life in which these domains are involved. Participants answer each item on a 5-point frequency scale, referring to the past 12 months. The tool provides an overall score, calculated as the mean of the scores on individual items, where higher values indicate a worse self-perception regarding cognitive functioning.
Metabolic outcomes -BMI
Body Mass Index (BMI) will be evaluated for every patient. Weight and height will be combined to report BMI in kg/m^2.
Metabolic outcomes - diabetes
Number of patients of the cohort with diabetes
Frequency cardiovascular disease
The number of times cardiovascular disease is observed in the cohort of patients
Compliance to screening for secondary cancers and vaccination
The number of times patients undergo screening and prevention for secondary cancers
Frequency others comorbidity
The number of times others comorbidities are observed in the cohort of patients
Adherence to healthy lifestyles - healthy diet
The endpoint will be assessed by MEDI-LITE (Mediterranean Literature) questionnaire that will be submitted to patients. Adherence to the Mediterranean diet assessed through the Medi-Lite score was found to be associated with abdominal obesity. The final score, obtained by summing these values, varies from 0 (low adherence) to 18 (high adherence).
Adherence to healthy lifestyles - Physical Activity
The endpoint will be assessed by IPAQ (International Physical Activity Questionnaire) that will be submitted to patients. This questionnaire measures the type and amount of physical activity the patient normally does. The questions refer to activity during the past 7 days at work, getting from place to place, and during leisure time. For the purpose of the questionnaire: one minute per week (MET) is what a patient consumes at rest. Therefore, 2 METS is twice what a patient spends at rest. To obtain a continuous variable score from the IPAQ (MET minutes per week), we will consider walking as 3.3 METS, moderate physical activity as 4 METS, and vigorous physical activity as 8 METS.
Measure of hand grip muscle strength
This end point will be measured through the use of the hand-grip dynamometer
Frequencies of negative Life-Style factors
Number of negative Life-Style factors associated with cardiotoxicity and metabolic syndrome.
Frequency of compliance between planned and effective follow-up via LS-SCP.
Number of times the plan prescribed by the LS-SCP is adhered to correctly in the cohort of patients

Full Information

First Posted
June 13, 2023
Last Updated
June 28, 2023
Sponsor
Fondazione Italiana Linfomi - ETS
search

1. Study Identification

Unique Protocol Identification Number
NCT05934084
Brief Title
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Official Title
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors: A Randomized Non-pharmacological Clinical Trial By The Fondazione Italiana Linfomi (FIL)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 1, 2023 (Anticipated)
Primary Completion Date
February 1, 2026 (Anticipated)
Study Completion Date
February 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione Italiana Linfomi - ETS

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).
Detailed Description
All patients will be assessed by validated questionnaires [EORTC QLQ-C30 (Quality of Life Questionnaire), SF12 (12-item Short Form Survey), MEDI-LITE (Mediterranean Literature questionnaire), CFSS (Chronic Fatigue Syndrome Self assessment), FAS (Fatigue Assessment Scale), Hospital Anxiety and Depression Scale (HAD-S)] and clinical assessment performed at baseline, at 6 and 12 months from the randomization. Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (Lifestyles implemented-Survivorship Care Plan (LS-SCP)) will be performed. Patients in the control arm will not receive any Survivorship Care Plan (SCP) or intervention and will be followed-up according to the best clinical practice, with questionnaires self-administration at 6 and 12 months from randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Keywords
Survivorship Care Plan, Lifestyles implemented-Survivorship Care Plan, Quality of Life, Lymphoma Survivors, Nutritional plan, Physical activity

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
It's a longitudinal study with two time-points (6 months and 12 months) after baseline (time 0) and the data will be evaluated by means of ANOVA for repeated measures, considering as baseline the global QoL of 75.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
552 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Arm (C)
Arm Type
No Intervention
Arm Description
Patients in the control arm will not receive any Survivorship Care Plan (SCP) or intervention and will be followed-up according to the best clinical practice, with questionnaires self-administration at 6 and 12 months from randomization.
Arm Title
Experimental Arm (E)
Arm Type
Experimental
Arm Description
Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity indication) for 6 months.
Intervention Type
Behavioral
Intervention Name(s)
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Intervention Description
Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
Primary Outcome Measure Information:
Title
Global quality of life
Description
The endpoint will be assessed by the European Organisation For Research And Treatment Of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) that will be submitted to patients. The EORTC QLQ-C30 consists of 30 items including five functioning scales (physical functioning, social functioning, role functioning, emotional functioning and cognitive functioning), nine symptom scales (fatigue, pain, nausea-vomiting, dyspnoea, sleep disturbances, appetite loss, diarrhoea, constipation and financial difficulties), and a global health status or quality of life (QOL) scale. On the 100-point metric, high scores for functioning scales and the global health status, or QOL, scale indicate high HR (health-related) QOL, while high scores on the symptom scales indicate a high symptom burden.
Time Frame
From study start up to 30 months
Secondary Outcome Measure Information:
Title
Impact of health on an individual's everyday life
Description
The endpoint will be assessed by the 12-Item Short Form Survey (SF-12) which will be submitted to patients. Survey scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
From study start up to 30 months
Title
Changes in psychosocial well-being
Description
The endpoint will be assessed by Hospital Anxiety and Depression Scale (HAD-S) questionnaire which will be submitted to patients. The HAD-S questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Time Frame
From study start up to 30 months
Title
Overall survival (OS)
Description
Overall survival, the percentage of patients alive of the cohort
Time Frame
From study start up to 30 months
Title
Frequencies of chronic fatigue (FAS);
Description
The number of times chronic fatigue is recorded in the cohort of patients
Time Frame
From study start up to 30 months
Title
Cognitive function
Description
The endpoint will be assessed by Cognitive Functioning Self-Assessment Scale (CFSS) questionnaire which will be submitted to patients. The Cognitive Functioning Self-Assessment Scale (CFSS) is a questionnaire designed for the self-reporting of cognitive functioning. Its 18 items cover cognitive domains such as attention, memory and spatial-temporal orientation. Each item describes an activity of daily life in which these domains are involved. Participants answer each item on a 5-point frequency scale, referring to the past 12 months. The tool provides an overall score, calculated as the mean of the scores on individual items, where higher values indicate a worse self-perception regarding cognitive functioning.
Time Frame
From study start up to 30 months
Title
Metabolic outcomes -BMI
Description
Body Mass Index (BMI) will be evaluated for every patient. Weight and height will be combined to report BMI in kg/m^2.
Time Frame
From study start up to 30 months
Title
Metabolic outcomes - diabetes
Description
Number of patients of the cohort with diabetes
Time Frame
From study start up to 30 months
Title
Frequency cardiovascular disease
Description
The number of times cardiovascular disease is observed in the cohort of patients
Time Frame
From study start up to 30 months
Title
Compliance to screening for secondary cancers and vaccination
Description
The number of times patients undergo screening and prevention for secondary cancers
Time Frame
From study start up to 30 months
Title
Frequency others comorbidity
Description
The number of times others comorbidities are observed in the cohort of patients
Time Frame
From study start up to 30 months
Title
Adherence to healthy lifestyles - healthy diet
Description
The endpoint will be assessed by MEDI-LITE (Mediterranean Literature) questionnaire that will be submitted to patients. Adherence to the Mediterranean diet assessed through the Medi-Lite score was found to be associated with abdominal obesity. The final score, obtained by summing these values, varies from 0 (low adherence) to 18 (high adherence).
Time Frame
From study start up to 30 months
Title
Adherence to healthy lifestyles - Physical Activity
Description
The endpoint will be assessed by IPAQ (International Physical Activity Questionnaire) that will be submitted to patients. This questionnaire measures the type and amount of physical activity the patient normally does. The questions refer to activity during the past 7 days at work, getting from place to place, and during leisure time. For the purpose of the questionnaire: one minute per week (MET) is what a patient consumes at rest. Therefore, 2 METS is twice what a patient spends at rest. To obtain a continuous variable score from the IPAQ (MET minutes per week), we will consider walking as 3.3 METS, moderate physical activity as 4 METS, and vigorous physical activity as 8 METS.
Time Frame
From study start up to 30 months
Title
Measure of hand grip muscle strength
Description
This end point will be measured through the use of the hand-grip dynamometer
Time Frame
From study start up to 30 months
Title
Frequencies of negative Life-Style factors
Description
Number of negative Life-Style factors associated with cardiotoxicity and metabolic syndrome.
Time Frame
From study start up to 30 months
Title
Frequency of compliance between planned and effective follow-up via LS-SCP.
Description
Number of times the plan prescribed by the LS-SCP is adhered to correctly in the cohort of patients
Time Frame
From study start up to 30 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-50 at initial treatment; Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL) or Primary mediastinal large B-cell lymphoma (PMBCL); Patients in Complete Remission (CR) after first-line therapy [ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin , cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2 guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adapted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL); Patients in remission for a minimum 3 years since the last treatment and a maximum of 10 years; Cumulative doxorubicin/ adriamycin dose received of at least 200 mg/mq (4 cycles of chemotherapy); Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensional speckle strain echocardiography) performed no later than three months prior to enrollment; Signature of a written informed consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate voluntarily in the study. Exclusion Criteria: Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers and adequately treated cone-biopsied in situ carcinoma of the cervix; Second line chemotherapy of stem cell transplant; Not able to perform physical activity; Grade >/=3 neuropathy; Vertebral fractures or stenosis of the vertebral canal; other bone fracture; Cardiovascular disease: arrhythmia >/= grade 2, hypertension >/ grade 2, left ventricular dysfunction >/= grade 2 pericardial disease/effusion any grade, myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathy any grade valvular hearth disease >/= grade 2, right ventricular dysfunction >/= grade 2; Venous thromboembolism or arterial thrombosis during last 6 months; Hemorrhage/ bleeding >/= grade 2 during last 6 months; Chronic lymphedema (arms and/ or limbs); Rheumatic disease or inflammatory bowel disease in systemic treatment; Any pleural effusion; If female, the patient is pregnant; Unwilling to comply to all required visits and procedures for the duration of study participation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Uffici Studi FIL
Phone
0599769918
Email
startup@filinf.it
First Name & Middle Initial & Last Name or Official Title & Degree
Uffici Studi FIL
Email
gestionestudi@filinf.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carla Minoia, MD
Organizational Affiliation
Bari, IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ancona - AOU Ospedali Riuniti - Clinica di Ematologia
City
Ancona
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guido Gini, MD
Phone
0715964562
Email
guido.gini@ospedaliriuniti.marche.it
First Name & Middle Initial & Last Name & Degree
Guido Gini, MD
Facility Name
Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati
City
Aviano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Spina, MD
Phone
0434659730
Email
mspina@cro.it
First Name & Middle Initial & Last Name & Degree
Michele Spina, Dr
Facility Name
Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia Cellulare
City
Bari
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carla Minoia, MD
Email
carlaminoia980@gmail.com
First Name & Middle Initial & Last Name & Degree
Carla Minoia, MD
Facility Name
Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia
City
Barletta
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Tarantini, MD
Phone
0883/577942
Email
giuseppetarantini0@gmail.com
First Name & Middle Initial & Last Name & Degree
Giuseppe Tarantini, MD
Facility Name
Ospedale S. Martino - UOC Oncologia
City
Belluno
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fable Zustovich, MD
Phone
0437514584
Email
fable.zustovich@aulss1.veneto.it
First Name & Middle Initial & Last Name & Degree
Fable Zustovich, MD
Facility Name
Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.
City
Bolzano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Turri, MD
Phone
0471438388
Email
gloria.turri@sabes.it
First Name & Middle Initial & Last Name & Degree
Gloria Turri, MD
Facility Name
ASST Spedali Civili di Brescia - Ematologia
City
Brescia
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara Pagani, MD
Phone
0303996269
Email
chiara.pagani@asst-spedalicivili.it
First Name & Middle Initial & Last Name & Degree
Chiara Pagani, MD
Facility Name
Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di Midollo
City
Brindisi
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Domenico Pastore, MD
Phone
0831537506
Email
domenico.pastore0@gmail.com
First Name & Middle Initial & Last Name & Degree
Domenico Pastore, MD
Facility Name
PO Sant'Elia ASP Caltanisetta - UOC Ematologia
City
Caltanissetta
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Enza Mitra, MD
Phone
0934559106
Email
ematologia.posantelia@asp.cl.it
First Name & Middle Initial & Last Name & Degree
Maria Enza Mitra, MD
Facility Name
Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia
City
Catania
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ugo Consoli, MD
Phone
0957595055
Email
ugo.consoli144@gmail.com
First Name & Middle Initial & Last Name & Degree
Ugo Consoli, MD
Facility Name
Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Emtologia
City
Catania
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annalisa Chiarenza, MD
Phone
095-7436155
Email
annalisa.chiarenza@gmail.com
First Name & Middle Initial & Last Name & Degree
Annalisa Chiarenza, MD
Facility Name
Ospedale Generale di zona Valduce - Oncoematologia
City
Como
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Steffanoni, MD
Phone
031324560
Email
sara.steffanoni@gmail.com
First Name & Middle Initial & Last Name & Degree
Sara Steffanoni, MD
Facility Name
Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di Ematologia
City
Firenze
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luca Nassi, MD
Phone
0557946445
Email
nassil@aou-careggi.toscana.it
First Name & Middle Initial & Last Name & Degree
Luca Nassi, MD
Facility Name
Ospedale Vito Fazzi - Ematologia
City
Lecce
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Di Renzo, MD
Phone
0832661923
Email
direnzo.ematolecce@gmail.com
First Name & Middle Initial & Last Name & Degree
Nicola Di Renzo, MD
Facility Name
ASST Ovest Milanese - Legnano - U.O.C. Ematologia Ospedale Civile di Legnano
City
Legnano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Franceschetti, MD
Phone
0331.449306
Email
silvia.franceschetti@asst-ovestmi.it
First Name & Middle Initial & Last Name & Degree
Silvia Franceschetti, MD
Facility Name
AOU G. Martino - U.O.C. Ematologia
City
Messina
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Allegra, MD
Phone
Tel: 090 2213253
Email
alessandro.allegra@unime.it
First Name & Middle Initial & Last Name & Degree
Alessandro Allegra, MD
Facility Name
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
City
Milano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vittorio Ruggero Zilioli, MD
Phone
0264442668
Email
vittorioruggero.zilioli@ospedaleniguarda.it
First Name & Middle Initial & Last Name & Degree
Vittorio Ruggero Zilioli, MD
Facility Name
IEO Istitito Europeo di Oncologia - Divisione Ematoncologia
City
Milano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simonetta Viviani, MD
Phone
0257489538
Email
simonetta.viviani@ieo.it
First Name & Middle Initial & Last Name & Degree
Simonetta Viviani, MD
Facility Name
Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda - Ematologia
City
Milano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesca Gaia Rossi, MD
Phone
0255033466
Email
francescagaia.rossi@policlinico.mi.it
First Name & Middle Initial & Last Name & Degree
Francesca Gaia Rossi, MD
Facility Name
Azienda Ospedaliero-Universitaria Policlinico di Modena - U.O. Oncologia
City
Modena
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessia Bari, MD
Phone
0594224798
Email
alessia.bari@unimore.it
First Name & Middle Initial & Last Name & Degree
Alessia Bari, MD
Facility Name
AOU Maggiore della Caritа di Novara - SCDU Ematologia
City
Novara
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Riccardo Bruna, MD
Phone
03213733880
Email
riccardo.bruna@med.uniupo.it
First Name & Middle Initial & Last Name & Degree
Riccardo Bruna, MD
Facility Name
AOU di Padova - Ematologia
City
Padova
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Greta Scapinello, MD
Phone
0498217809
Email
greta.scapinello@aopd.veneto.it
First Name & Middle Initial & Last Name & Degree
Greta Scapinello, MD
Facility Name
I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1
City
Padova
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dario Marino, MD
Phone
0498215621
Email
dario.marino@iov.veneto.it
First Name & Middle Initial & Last Name & Degree
Dario Marino, MD
Facility Name
Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia
City
Pagani
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catello Califano, MD
Phone
081921364
Email
c.califano@aslsalerno.it
First Name & Middle Initial & Last Name & Degree
Catello Califano, MD
Facility Name
AOU Policlinico Giaccone - Ematologia
City
Palermo
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salvatrice Mancuso, MD
Phone
0916554505
Email
salvatrice.mancuso@unipa.it
First Name & Middle Initial & Last Name & Degree
Salvatrice Mancuso, MD
Facility Name
P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi
City
Pescara
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elsa Pennese, MD
First Name & Middle Initial & Last Name & Degree
Elsa Pennese, MD
Facility Name
Ospedale Guglielmo da Saliceto - U.O.Ematologia
City
Piacenza
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annalisa Arcari, MD
Phone
0523303724
Email
a.arcari@ausl.pc.it
First Name & Middle Initial & Last Name & Degree
Annalisa Arcari, MD
Facility Name
AOU Pisana - U.O. Ematologia
City
Pisa
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Galimberti, MD
Phone
050993488
Email
sara.galimberti@med.unipi.it
First Name & Middle Initial & Last Name & Degree
Sara Galimberti, MD
Facility Name
A.O.R. "San Carlo" - U.O. Ematologia
City
Potenza
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Cimminiello, MD
Phone
0971 612456
Email
miki-doc@virgilio.it
First Name & Middle Initial & Last Name & Degree
Michele Cimminiello, MD
Facility Name
Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia
City
Reggio Emilia
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Arletti, MD
Phone
0522296623
Email
arletti.laura@ausl.re.it
First Name & Middle Initial & Last Name & Degree
Laura Arletti, MD
Facility Name
Ospedale degli Infermi di Rimini - U.O. di Ematologia
City
Rimini
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Rotondo, MD
Phone
0541705603
Email
frotondo824@gmail.com
First Name & Middle Initial & Last Name & Degree
Francesco Rotondo, MD
Facility Name
AO Sant'Andrea - Ematologia
City
Roma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agostino Tafuri, MD
Phone
0633775842
Email
agostino.tafuri@ospedalesantandrea.it
First Name & Middle Initial & Last Name & Degree
Agostino Tafuri, MD
Facility Name
Ospedale S. Eugenio - UOC Ematologia
City
Roma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisabetta Abruzzese, MD
Phone
0651008984
Email
elisabetta.abruzzese@uniroma2.it
First Name & Middle Initial & Last Name & Degree
Elisabetta Abruzzese, MD
Facility Name
Policlinico Tor Vergata - Ematologia
City
Roma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Giulia Zizzari, MD
Phone
0620903224
Email
annadot86@hotmail.it
First Name & Middle Initial & Last Name & Degree
Anna Giulia Zizzari, MD
Facility Name
Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare
City
Roma
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ombretta Annibali, MD
Phone
06225411
Email
o.annibali@policlinicocampus.it
First Name & Middle Initial & Last Name & Degree
Ombretta Annibali, MD
Facility Name
Istituto Clinico Humanitas - U.O. Ematologia
City
Rozzano
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Santoro Armando, MD
Phone
0282244080
Email
armando.santoro@humanitas.it
First Name & Middle Initial & Last Name & Degree
Santoro Armando, MD
Facility Name
AOU di Sassari - Ematologia
City
Sassari
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto Massaiu, MD
Phone
079229883
Email
robertomassaiu1@gmail.com
First Name & Middle Initial & Last Name & Degree
Roberto Massaiu, MD
Facility Name
Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico
City
Sassuolo
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Bigliardi, MD
Phone
0536846162
Email
s.bigliardi@ausl.mo.it
First Name & Middle Initial & Last Name & Degree
Sara Bigliardi, MD
Facility Name
A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria
City
Torino
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Federica Cavallo, MD
Phone
0116334264
Email
f.cavallo@unito.it
First Name & Middle Initial & Last Name & Degree
Federica Cavallo, MD
Facility Name
Ospedale Ca Foncello - S.C di Ematologia
City
Treviso
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisabetta Scarpa, MD
Phone
0422328490
Email
elisabetta.scarpa@aulss2.veneto.it
First Name & Middle Initial & Last Name & Degree
Elisabetta Scarpa, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

We'll reach out to this number within 24 hrs